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Abstract: Severe asthma is defined as asthma that requires treatment with high-dose inhaled 
corticosteroids (ICSs) plus a second controller and/or systemic corticosteroids to prevent it from 
becoming uncontrolled or that remains uncontrolled despite this therapy. This definition has 
limitations: 1) it does not define any biological characteristic that distinguishes severe asthma 
from asthma in general and 2) it relies on the clinical interpretation of asthma symptoms that 
are not specific. Actually, wheezing, dyspnea, cough and chest tightness may be caused by the 
comorbidities (such as rhinosinusitis, obesity and vocal cord dysfunction [VCD]) which are 
associated with asthma. In clinical practice, clinicians are often prone to diagnose uncontrolled 
asthma and increase doses of ICSs without considering the comorbidities,  resulting in poor 
control of symptoms. This commentary wishes the clinicians to focus on the comorbidities 
of asthma, particularly in patients with severe asthma, because the correct diagnosis of these 
comorbidities implies specific treatments that lead to a better asthma control.
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The recent increase in therapeutic options for the treatment of severe asthma1 has 
increased the importance of diagnosis and asthma phenotyping. According to Inter-
national European Respiratory Society (ERS)/American Thoracic Society (ATS) task 
force, severe asthma is defined as asthma that requires treatment with high-dose ICSs 
plus a second controller and/or systemic corticosteroids to prevent it from becoming 
uncontrolled or that remains uncontrolled despite this therapy.2 The criteria for uncon-
trolled asthma include: poor symptom control, frequent severe exacerbations or one 
serious exacerbation that requires hospitalization, intensive care unit (ICU) stay or 
mechanical ventilation in the previous year or airflow limitation. This definition has 
limitations: it does not define any biological characteristic that distinguishes severe 
asthma from asthma in general and it relies on the clinical interpretation of symptoms 
that should be attributed to asthma. However, asthma has no characteristic symptoms 
because wheezing, dyspnea, cough and chest tightness are the symptoms  that are not 
specific, as these  are caused by the comorbidities associated with asthma. Here, we 
use the term asthma comorbidity to refer to a condition that influences asthma sever-
ity, management or diagnosis, with consequent misattribution of shared symptoms. 
In pediatric patients, an association of asthma with cystic fibrosis (CF) may occur, by 
coincidence to the high prevalence of asthma in children, the so-called CF asthma.3 The 
patient with CF is reported as having concomitant asthma if, in the treating physician’s 
opinion, asthma contributes significantly to the patient’s lung disease. The diagnosis of 
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asthma is suggested by episodes of acute airway obstruction 
reversed by bronchodilators, a strong family history of asthma 
and/or evidence of atopy or laboratory evidence of allergy 
(ie, prick tests positive for common inhalant allergens). In the 
elderly, it is not uncommon to evaluate patients with persistent 
airflow limitation and smoking history, with some features 
usually associated with asthma, such as eosinophilic airway 
inflammation, the so-called asthma COPD overlap syndrome 
(ACOS), as defined by recent consensus criteria.4 Clinicians 
should enquire about smoking habit of their difficult-to-treat 
asthma patients, as smoking is associated with reduced 
expression of histone deacetylase (HDAC2). HDAC2 appears 
to mediate the action of steroids to switch off activated inflam-
matory genes, but in smokers with asthma, HDAC2 activ-
ity and expression are reduced by oxidative stress through 
activation of phosphoinositide 3-kinase δ.5 We will consider 
in more detail some comorbidities which, based upon the 
authors’ experience, have a major impact on the management 
of asthmatic patients. In the clinical scenario of a patient who 
had previously received the diagnosis of asthma, whenever 
cough, dyspnea and wheezing are due to asthma comorbidi-
ties, such as rhinosinusitis, obesity and VCD, clinicians are 
prone to diagnose uncontrolled asthma and increase doses of 
ICSs, resulting in poor control of symptoms. This condition 
fulfills the criteria of severe asthma, and the correct diagnosis 
should be asthma with severe comorbidities.
The comorbidities may result in misdiagnosis, misinter-
pretation of symptoms, aggravation of one or more diseases. 
In contrast, the recognition of comorbidities facilitates more 
appropriate therapy or reduction of potentially risky therapies, 
such as systemic corticosteroids.
Specific treatments of comorbidities have been shown 
to improve asthma control. According to Ragab et al,6 both 
medical and surgical treatments of chronic rhinosinusitis 
(CRS) were associated with subjective and objective improve-
ments in asthma. Some new biological therapies targeting IL5 
and IL4/IL13 may improve nasal polyps score and decrease 
asthma exacerbation rate.1,7,8 The proportion of patients with 
symptoms of CRS has been reported to be as high as 74% in 
patients with severe steroid-dependent asthma, who showed 
a severe sino-nasal involvement as evaluated by computed 
tomography (CT) scan imaging.9 Clinicians should consider 
the diagnosis of CRS based upon the presence of at least 
two of the four cardinal signs/symptoms (anterior and/or 
posterior nasal mucopurulent drainage, nasal obstruction/
nasal blockage/congestion, facial pain, pressure and/or full-
ness and reduction or loss of sense of smell) in combination 
with objective evidence of mucosal inflammation.10 Objective 
evidence of mucosal inflammation requires demonstration of 
one or more of the following findings, using nasal endoscopy 
and/or CT imaging: purulent mucus or edema in the middle 
meatus or ethmoid regions, polyps in the nasal cavity or the 
middle meatus, radiographic imaging demonstrating mucosal 
thickening or partial or complete opacification of the para-
nasal sinuses. In obese patients, the risk of misdiagnosing 
asthma and/or its severity is particularly high. Among 91 
subjects (mean body mass index [BMI], 38 kg/m2) with 
a diagnosis of asthma, taking a mean beclomethasone-
equivalent dose of 1,273 mg/day, 36.3% had no bronchial 
hyperresponsiveness (possible misclassification of asthma 
diagnosis).11 Therefore, clinicians should not accept asthma 
diagnosis based on symptoms alone particularly in obese 
subjects. The objective measurements of variable airflow 
obstruction or bronchial hyperresponsiveness are important 
to confirm the diagnosis of asthma in obese patients. If obese 
patients who are receiving asthma treatment are still report-
ing dyspnea and exercise intolerance, it is advised to check 
lung function and, if normal, to step down asthma therapy 
and recheck respiratory function. Otherwise, a misdiagnosis 
may lead to inappropriate treatment, with an increased risk of 
side effects and increased costs.12 On the other hand, bariatric 
surgery not only improved small airway function, which could 
explain the improvement of asthma control and quality of 
life, but also induced a decrease in systemic and bronchial 
inflammation in morbidly obese patients with asthma.13
Prevalence of dysfunctional breathing, evaluated by 
Nijmegen questionnaire, in patients treated for asthma in 
primary care has been estimated to be 35% among women 
and 20% among men,14 and reports of VCD mimicking severe 
asthma are not rare.15,16 VCD is defined by the complete or 
partial adduction of the vocal folds with inspiration and/or 
expiration. This process seems to occur in response to irrita-
tion of the larynx or hypopharynx or secondary to emotional or 
physical stress.17 The symptoms of VCD include high-pitched 
wheezing, usually more prominent with inspiration, hoarse-
ness, dysphonia and cough.18 Symptoms are often episodic 
with rapid resolution, with or without therapy. Patients may be 
misdiagnosed with asthma when VCD is responsible for their 
symptoms or have VCD and asthma simultaneously. The use 
of the flow volume loop may be helpful in recognizing VCD. 
The inspiratory loop typically exhibits decreased flow rate 
with variability in flow, resulting in a wavy, flattened curve 
instead of the typical smooth, oval appearance. A speech 
therapist or speech pathologist, knowledgeable about VCD, 
can be very helpful in treating this disorder.19 Over half of 
the patients treated for asthma in the community who have 
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symptoms suggestive of dysfunctional breathing showed a 
clinically relevant improvement in quality of life following a 
brief physiotherapy intervention, and the improvement was 
maintained to be over 25% 6 months after the  intervention.20 
In conclusion, we wish  the clinicians to focus on the comor-
bidities of asthma, particularly in patients with severe asthma, 
because the correct diagnosis of these comorbidities implies 
specific treatments that lead to a better asthma control.
Disclosure
The authors report no conflicts of interest in this work.
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